Prosthetic Joint Infection Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global prosthetic joint infection treatment market is predicted to expand at a CAGR of 6.0% from 2024 to 2031. In 2024, the market stood at US$ 109 million and is thus expected to reach US$ 160 million by 2031-end.
Factors Influencing the Demand Growth for PJI Treatment
The prosthetic joint infection (PJI) treatment market is witnessing significant growth fueled by the emphasis on employing debridement, antibiotics, and irrigation with implant retention (DAIR) procedures. DAIR offers simplicity, shorter recovery times, and improved quality of life for patients, highlighting its importance in PJI management. Additionally, understanding the microbial biofilm paradigm is crucial for developing targeted therapies and preventive strategies to combat biofilm-forming bacteria, which are resistant to immune responses and antibiotics.
Main Challenges Faced by PJI Treatment Providers
Despite the potential of DAIR procedures, their success can be limited, and factors like antibiotic resistance pose challenges to treatment outcomes. Gram-negative microbes and methicillin-resistant Staphylococcus aureus (MRSA) infections can result in poor outcomes, necessitating caution and innovative treatment approaches. Collaboration among multidisciplinary teams is essential to address these challenges effectively.
Country-wise Insights
• United States: The high prevalence of healthcare-associated infections (HCAIs) drives demand for PJI treatment, emphasizing the importance of infection control measures and effective therapeutic strategies.
• India: Growing medical tourism, supported by skilled healthcare professionals and government initiatives, contributes to the expansion of the PJI treatment market in India.
• China: The rising number of joint replacement surgeries leads to increased demand for PJI treatment solutions, posing a significant therapeutic challenge to the Chinese healthcare system.
Category-wise Insights
• Pharmaceutical Agents: Glycopeptides, including vancomycin and teicoplanin, are widely utilized for treating PJIs due to their ability to target resistant strains and provide effective treatment.
• Infection Types: Post-operative infections, particularly those caused by Staphylococcus aureus, require specialist care and effective treatment solutions to address their complexity.
• Treatment Methods: Intravenous administration of antibiotics ensures enhanced efficacy by delivering antibiotics directly to the infection site, driving revenue growth in the market.
Competitive Analysis
The PJI treatment market is highly fragmented, with several competitors offering products and services globally. Companies are focusing on business expansion, innovation, and collaboration to meet patients' demands and grow their market presence.
• Pfizer Inc.
• Novartis AG
• Mylan N.V.
• Teva Pharmaceuticals
• Merck & Co.
• Eli Lilly & Company
• AstraZeneca plc.
• Lupin Limited
• Dr Reddys Laboratories
• Aurobindo Pharma Ltd
• GSK plc.
• Sun Pharmaceutical Industries Ltd.
• Cipla ltd.
Key Segments of Prosthetic Joint Infection Treatment Industry Research
By Drug:
• Aminoglycosides
• Glycopeptides
• Rifamycin
• Lincosamide
• Penicillin
• Other Antibiotics
By Infection:
• Pre-operative Infection
• Post-operative Infection
By Route of Administration:
• Oral
• Intravenous
By Pathogen:
• Staphylococcus Aureus
• Coagulase-negative Staphylococcus
• Candida Species
• Enterococcus Species
• Other Pathogens
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Sales
By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.
- 1. Executive Summary
- 1.1. Global Prosthetic Joint Infections Treatment Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2023
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Prosthetic Joint Infections Treatment Market Outlook, 2018 – 2031
- 3.1. Global Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2018 – 2031
- 3.1.1. Key Highlights
- 3.1.1.1. Aminoglycosides
- 3.1.1.2. Glycopeptides
- 3.1.1.3. Rifamycin
- 3.1.1.4. Lincosamide
- 3.1.1.5. Penicillin
- 3.1.1.6. Other Antibiotics
- 3.2. Global Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2018 – 2031
- 3.2.1. Key Highlights
- 3.2.1.1. Pre-operative Infection
- 3.2.1.2. Post-operative Infection
- 3.3. Global Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2018 – 2031
- 3.3.1. Key Highlights
- 3.3.1.1. Staphylococcus Aureus
- 3.3.1.2. Coagulase-negative Staphylococcus
- 3.3.1.3. Candida Species
- 3.3.1.4. Enterococcus Species
- 3.3.1.5. Other Pathogens
- 3.4. Global Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 3.4.1. Key Highlights
- 3.4.1.1. Oral
- 3.4.1.2. Intravenous
- 3.5. Global Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 3.5.1. Key Highlights
- 3.5.1.1. Hospital Pharmacies
- 3.5.1.2. Retail Pharmacies
- 3.5.1.3. Drug Stores
- 3.5.1.4. Online Sales
- 3.6. Global Prosthetic Joint Infections Treatment Market Outlook, by Region, Value (US$ Mn), 2018 – 2031
- 3.6.1. Key Highlights
- 3.6.1.1. North America
- 3.6.1.2. Europe
- 3.6.1.3. Asia Pacific
- 3.6.1.4. Latin America
- 3.6.1.5. Middle East & Africa
- 4. North America Prosthetic Joint Infections Treatment Market Outlook, 2018 – 2031
- 4.1. North America Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2018 – 2031
- 4.1.1. Key Highlights
- 4.1.1.1. Aminoglycosides
- 4.1.1.2. Glycopeptides
- 4.1.1.3. Rifamycin
- 4.1.1.4. Lincosamide
- 4.1.1.5. Penicillin
- 4.1.1.6. Other Antibiotics
- 4.2. North America Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2018 – 2031
- 4.2.1. Key Highlights
- 4.2.1.1. Pre-operative Infection
- 4.2.1.2. Post-operative Infection
- 4.3. North America Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2018 – 2031
- 4.3.1. Key Highlights
- 4.3.1.1. Staphylococcus Aureus
- 4.3.1.2. Coagulase-negative Staphylococcus
- 4.3.1.3. Candida Species
- 4.3.1.4. Enterococcus Species
- 4.3.1.5. Other Pathogens
- 4.4. North America Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 4.4.1. Key Highlights
- 4.4.1.1. Oral
- 4.4.1.2. Intravenous
- 4.5. North America Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 4.5.1. Key Highlights
- 4.5.1.1. Hospital Pharmacies
- 4.5.1.2. Retail Pharmacies
- 4.5.1.3. Drug Stores
- 4.5.1.4. Online Sales
- 4.5.2. BPS Analysis/Market Attractiveness Analysis
- 4.6. North America Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 4.6.1. Key Highlights
- 4.6.1.1. U.S. Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 4.6.1.2. U.S. Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 4.6.1.3. U.S. Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 4.6.1.4. U.S. Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 4.6.1.5. U.S. Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 4.6.1.6. Canada Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 4.6.1.7. Canada Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 4.6.1.8. Canada Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 4.6.1.9. Canada Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 4.6.1.10. Canada Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 4.6.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Prosthetic Joint Infections Treatment Market Outlook, 2018 – 2031
- 5.1. Europe Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2018 – 2031
- 5.1.1. Key Highlights
- 5.1.1.1. Aminoglycosides
- 5.1.1.2. Glycopeptides
- 5.1.1.3. Rifamycin
- 5.1.1.4. Lincosamide
- 5.1.1.5. Penicillin
- 5.1.1.6. Other Antibiotics
- 5.2. Europe Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2018 – 2031
- 5.2.1. Key Highlights
- 5.2.1.1. Pre-operative Infection
- 5.2.1.2. Post-operative Infection
- 5.3. Europe Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2018 – 2031
- 5.3.1. Key Highlights
- 5.3.1.1. Staphylococcus Aureus
- 5.3.1.2. Coagulase-negative Staphylococcus
- 5.3.1.3. Candida Species
- 5.3.1.4. Enterococcus Species
- 5.3.1.5. Other Pathogens
- 5.4. Europe Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.4.1. Key Highlights
- 5.4.1.1. Oral
- 5.4.1.2. Intravenous
- 5.5. Europe Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.5.1. Key Highlights
- 5.5.1.1. Hospital Pharmacies
- 5.5.1.2. Retail Pharmacies
- 5.5.1.3. Drug Stores
- 5.5.1.4. Online Sales
- 5.5.2. BPS Analysis/Market Attractiveness Analysis
- 5.6. Europe Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 5.6.1. Key Highlights
- 5.6.1.1. Germany Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 5.6.1.2. Germany Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 5.6.1.3. Germany Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 5.6.1.4. Germany Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.6.1.5. Germany Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.6.1.6. U.K. Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 5.6.1.7. U.K. Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 5.6.1.8. U.K. Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 5.6.1.9. U.K. Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.6.1.10. U.K. Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.6.1.11. France Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 5.6.1.12. France Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 5.6.1.13. France Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 5.6.1.14. France Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.6.1.15. France Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.6.1.16. Italy Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 5.6.1.17. Italy Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 5.6.1.18. Italy Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 5.6.1.19. Italy Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.6.1.20. Italy Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.6.1.21. Turkey Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 5.6.1.22. Turkey Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 5.6.1.23. Turkey Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 5.6.1.24. Turkey Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.6.1.25. Turkey Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.6.1.26. Russia Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 5.6.1.27. Russia Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 5.6.1.28. Russia Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 5.6.1.29. Russia Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.6.1.30. Russia Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.6.1.31. Rest of Europe Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 5.6.1.32. Rest of Europe Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 5.6.1.33. Rest of Europe Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 5.6.1.34. Rest of Europe Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.6.1.35. Rest of Europe Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.6.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, 2018 – 2031
- 6.1. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2018 – 2031
- 6.1.1. Key Highlights
- 6.1.1.1. Aminoglycosides
- 6.1.1.2. Glycopeptides
- 6.1.1.3. Rifamycin
- 6.1.1.4. Lincosamide
- 6.1.1.5. Penicillin
- 6.1.1.6. Other Antibiotics
- 6.2. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2018 – 2031
- 6.2.1. Key Highlights
- 6.2.1.1. Pre-operative Infection
- 6.2.1.2. Post-operative Infection
- 6.3. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2018 – 2031
- 6.3.1. Key Highlights
- 6.3.1.1. Staphylococcus Aureus
- 6.3.1.2. Coagulase-negative Staphylococcus
- 6.3.1.3. Candida Species
- 6.3.1.4. Enterococcus Species
- 6.3.1.5. Other Pathogens
- 6.4. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.4.1. Key Highlights
- 6.4.1.1. Oral
- 6.4.1.2. Intravenous
- 6.5. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.5.1. Key Highlights
- 6.5.1.1. Hospital Pharmacies
- 6.5.1.2. Retail Pharmacies
- 6.5.1.3. Drug Stores
- 6.5.1.4. Online Sales
- 6.5.2. BPS Analysis/Market Attractiveness Analysis
- 6.6. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 6.6.1. Key Highlights
- 6.6.1.1. China Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 6.6.1.2. China Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 6.6.1.3. China Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 6.6.1.4. China Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.6.1.5. China Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.6.1.6. Japan Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 6.6.1.7. Japan Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 6.6.1.8. Japan Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 6.6.1.9. Japan Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.6.1.10. Japan Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.6.1.11. South Korea Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 6.6.1.12. South Korea Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 6.6.1.13. South Korea Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 6.6.1.14. South Korea Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.6.1.15. South Korea Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.6.1.16. India Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 6.6.1.17. India Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 6.6.1.18. India Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 6.6.1.19. India Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.6.1.20. India Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.6.1.21. Southeast Asia Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 6.6.1.22. Southeast Asia Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 6.6.1.23. Southeast Asia Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 6.6.1.24. Southeast Asia Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.6.1.25. Southeast Asia Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.6.1.26. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 6.6.1.27. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 6.6.1.28. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 6.6.1.29. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.6.1.30. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.6.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Prosthetic Joint Infections Treatment Market Outlook, 2018 – 2031
- 7.1. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2018 – 2031
- 7.1.1. Key Highlights
- 7.1.1.1. Aminoglycosides
- 7.1.1.2. Glycopeptides
- 7.1.1.3. Rifamycin
- 7.1.1.4. Lincosamide
- 7.1.1.5. Penicillin
- 7.1.1.6. Other Antibiotics
- 7.2. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2018 – 2031
- 7.2.1.1. Pre-operative Infection
- 7.2.1.2. Post-operative Infection
- 7.3. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2018 – 2031
- 7.3.1. Key Highlights
- 7.3.1.1. Staphylococcus Aureus
- 7.3.1.2. Coagulase-negative Staphylococcus
- 7.3.1.3. Candida Species
- 7.3.1.4. Enterococcus Species
- 7.3.1.5. Other Pathogens
- 7.4. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.4.1. Key Highlights
- 7.4.1.1. Oral
- 7.4.1.2. Intravenous
- 7.5. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.5.1. Key Highlights
- 7.5.1.1. Hospital Pharmacies
- 7.5.1.2. Retail Pharmacies
- 7.5.1.3. Drug Stores
- 7.5.1.4. Online Sales
- 7.5.2. BPS Analysis/Market Attractiveness Analysis
- 7.6. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 7.6.1. Key Highlights
- 7.6.1.1. Brazil Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 7.6.1.2. Brazil Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 7.6.1.3. Brazil Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 7.6.1.4. Brazil Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.6.1.5. Brazil Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.6.1.6. Mexico Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 7.6.1.7. Mexico Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 7.6.1.8. Mexico Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 7.6.1.9. Mexico Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.6.1.10. Mexico Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.6.1.11. Argentina Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 7.6.1.12. Argentina Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 7.6.1.13. Argentina Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 7.6.1.14. Argentina Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.6.1.15. Argentina Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.6.1.16. Rest of Latin America Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 7.6.1.17. Rest of Latin America Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 7.6.1.18. Rest of Latin America Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 7.6.1.19. Rest of Latin America Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.6.1.20. Rest of Latin America Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.6.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, 2018 – 2031
- 8.1. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2018 – 2031
- 8.1.1. Key Highlights
- 8.1.1.1. Aminoglycosides
- 8.1.1.2. Glycopeptides
- 8.1.1.3. Rifamycin
- 8.1.1.4. Lincosamide
- 8.1.1.5. Penicillin
- 8.1.1.6. Other Antibiotics
- 8.2. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2018 – 2031
- 8.2.1. Key Highlights
- 8.2.1.1. Pre-operative Infection
- 8.2.1.2. Post-operative Infection
- 8.3. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2018 – 2031
- 8.3.1. Key Highlights
- 8.3.1.1. Staphylococcus Aureus
- 8.3.1.2. Coagulase-negative Staphylococcus
- 8.3.1.3. Candida Species
- 8.3.1.4. Enterococcus Species
- 8.3.1.5. Other Pathogens
- 8.4. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.4.1. Key Highlights
- 8.4.1.1. Oral
- 8.4.1.2. Intravenous
- 8.5. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.5.1. Key Highlights
- 8.5.1.1. Hospital Pharmacies
- 8.5.1.2. Retail Pharmacies
- 8.5.1.3. Drug Stores
- 8.5.1.4. Online Sales
- 8.5.2. BPS Analysis/Market Attractiveness Analysis
- 8.6. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 8.6.1. Key Highlights
- 8.6.1.1. GCC Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 8.6.1.2. GCC Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 8.6.1.3. GCC Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 8.6.1.4. GCC Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.6.1.5. GCC Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.6.1.6. South Africa Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 8.6.1.7. South Africa Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 8.6.1.8. South Africa Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 8.6.1.9. South Africa Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.6.1.10. South Africa Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.6.1.11. Egypt Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 8.6.1.12. Egypt Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 8.6.1.13. Egypt Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 8.6.1.14. Egypt Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.6.1.15. Egypt Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.6.1.16. Nigeria Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 8.6.1.17. Nigeria Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 8.6.1.18. Nigeria Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 8.6.1.19. Nigeria Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.6.1.20. Nigeria Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.6.1.21. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2018 – 2031
- 8.6.1.22. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2018 – 2031
- 8.6.1.23. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2018 – 2031
- 8.6.1.24. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.6.1.25. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.6.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. Product vs Indication Heatmap
- 9.2. Company Market Share Analysis, 2022
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Pfizer Inc.
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Development
- 9.4.2. Novartis AG
- 9.4.2.1. Company Overview
- 9.4.2.2. Product Portfolio
- 9.4.2.3. Financial Overview
- 9.4.2.4. Business Strategies and Development
- 9.4.3. Mylan N.V.
- 9.4.3.1. Company Overview
- 9.4.3.2. Product Portfolio
- 9.4.3.3. Financial Overview
- 9.4.3.4. Business Strategies and Development
- 9.4.4. Teva Pharmaceuticals
- 9.4.4.1. Company Overview
- 9.4.4.2. Product Portfolio
- 9.4.4.3. Financial Overview
- 9.4.4.4. Business Strategies and Development
- 9.4.5. Merck & Co.
- 9.4.5.1. Company Overview
- 9.4.5.2. Product Portfolio
- 9.4.5.3. Financial Overview
- 9.4.5.4. Business Strategies and Development
- 9.4.6. Eli Lilly & Company
- 9.4.6.1. Company Overview
- 9.4.6.2. Product Portfolio
- 9.4.6.3. Financial Overview
- 9.4.6.4. Business Strategies and Development
- 9.4.7. AstraZeneca PLC
- 9.4.7.1. Company Overview
- 9.4.7.2. Product Portfolio
- 9.4.7.3. Financial Overview
- 9.4.7.4. Business Strategies and Development
- 9.4.8. Lupin Limited
- 9.4.8.1. Company Overview
- 9.4.8.2. Product Portfolio
- 9.4.8.3. Financial Overview
- 9.4.8.4. Business Strategies and Development
- 9.4.9. Dr. Reddys Laboratories
- 9.4.9.1. Company Overview
- 9.4.9.2. Product Portfolio
- 9.4.9.3. Financial Overview
- 9.4.9.4. Business Strategies and Development
- 9.4.10. Aurobindo Pharma Ltd.
- 9.4.10.1. Company Overview
- 9.4.10.2. Product Portfolio
- 9.4.10.3. Financial Overview
- 9.4.10.4. Business Strategies and Development
- 9.4.11. GSK PLC
- 9.4.11.1. Company Overview
- 9.4.11.2. Product Portfolio
- 9.4.11.3. Financial Overview
- 9.4.11.4. Business Strategies and Development
- 9.4.12. Sun Pharmaceutical Industries Ltd.
- 9.4.12.1. Company Overview
- 9.4.12.2. Product Portfolio
- 9.4.12.3. Financial Overview
- 9.4.12.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook